Ticker Details
Acrivon Therapeutics, Inc.
IPO Date:	November 15, 2022
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$94.71M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.27 | 4.29%
Avg Daily Range (30 D):	$0.08 | 4.25%
Avg Daily Range (90 D):	$0.07 | 3.86%

Institutional Daily Volume
Avg Daily Volume:	.42M
Avg Daily Volume (30 D):	.4M
Avg Daily Volume (90 D):	.49M

Trade Size
Avg Trade Size (Sh.):	174
Avg Trade Size (Sh.) (30 D):	163
Avg Trade Size (Sh.) (90 D):	205

Institutional Trades
Total Institutional Trades:	24
Avg Institutional Trade:	$2.27M
Avg Institutional Trade (30 D):	$.51M
Avg Institutional Trade (90 D):	$2.68M
Avg Institutional Trade Volume:	.39M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.74M
Avg Closing Trade (30 D):	$.51M
Avg Closing Trade (90 D):	$.52M
Avg Closing Volume:	317.24K

News

Apr 17, 2026 @ 8:00 PM Acrivon to Highlight Preclinical Data with Three P... Source: Not Specified

Mar 17, 2026 @ 9:54 PM Acrivon Therapeutics to Present Pre-Clinical AP3 D... Source: Not Specified

Jul 15, 2025 @ 5:00 PM Endometrial Cancer Clinical Trial Pipeline Insight... Source: Delveinsight

Sep 14, 2024 @ 7:10 AM Acrivon Therapeutics Reports Positive Endometrial ... Source: N/A

Jul 10, 2024 @ 1:01 PM Athira (ATHA) Completes Dosing in Alzheimer's Stud... Source: N/A

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.88	$-.43	$-.49
Diluted EPS	$-1.88	$-.43	$-.49
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-74.23M	$-17.96M	$-19.04M
Operating Income / Loss	$-78.37M	$-18.67M	$-19.9M
Cost of Revenue
Net Cash Flow	$-.48M	$7.35M	$-7.44M
PE Ratio